SCOPUS 정보 검색 플랫폼

Nature Reviews Drug Discovery

Volumn 9, Issue 6, 2010, Pages 427-428

Targeted cancer therapies

(1) Aggarwal, Saurabh a

a NONE (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BSI 201; CAPECITABINE; CETUXIMAB; CYTOTOXIC AGENT; DASATINIB; DENOSUMAB; FLUOROURACIL; FOLINIC ACID; IMATINIB; IPILIMUMAB; NILOTINIB; OMACETAXINE; OXALIPLATIN; PERTUZUMAB; PLATINUM COMPLEX; RIDAFOROLIMUS; RITUXIMAB; TANESPIMYCIN; TANESPIMYCIN HYDROQUINONE; TICILIMUMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; VANDETANIB; XL 184; ZALUTUMUMAB;

BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; GASTROINTESTINAL STROMAL TUMOR; HEAD AND NECK CANCER; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MULTIPLE MYELOMA; ONCOLOGY; PRIORITY JOURNAL; SARCOMA; SHORT SURVEY; THYROID MEDULLARY CARCINOMA; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMMERCE; DRUG COSTS; HUMANS; NEOPLASMS;

EID: 77953143235 PISSN: 14741776 EISSN: 14741784 Source Type: Journal
DOI: 10.1038/nrd3186 Document Type: Short Survey

Times cited : (164)

References (9)

1
- 78751519790
- IMS Health. Press release (1 April) IMS Health website [online]
- IMS Health. Press release (1 April). IMS Health reports U.S. prescription sales grew 5.1 percent in 2009, to $300.3 billion. IMS Health website [online] http://www.imshealth.com/portal/site/imshealth/menuitem. a46c6d4df3db4b3d88f61101941 8c22a/?vgnextoid=d690a27e9d5b7210VgnVCM100 000ed152ca2RCRD&vgnextchannel=41a67900b55a 5110VgnVCM10000071812ca2RCRD& vgnextfmt=def ault (2010).
- (2010) IMS Health Reports U.S. Prescription Sales Grew 5.1 Percent in 2009, to $300.3 Billion

2
- 33744466541
- Antiangiogenic therapy: A universal chemosensitization strategy for cancer?
- Kerbel, R. S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312, 1171-1175 (2006).
- (2006) Science , vol.312 , pp. 1171-1175
- Kerbel, R.S.¹

3
- 35548968518
- Cancer: Mixing cocktails
- Sawyers, C. L. Cancer: mixing cocktails. Nature 449, 993-996 (2007).
- (2007) Nature , vol.449 , pp. 993-996
- Sawyers, C.L.¹

4
- 59749091477
- Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer
- Tol, J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572 (2009).
- (2009) N. Engl. J. Med. , vol.360 , pp. 563-572
- Tol, J.¹

5
- 67650874081
- Cancer statistics 2009
- Jemal, A. et al. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
- (2009) CA Cancer J. Clin. , vol.59 , pp. 225-249
- Jemal, A.¹

6
- 67349193628
- Chronic myelogenous leukaemia market
- Storey, S. Chronic myelogenous leukaemia market. Nature Rev. Drug Discov. 8, 447-448 (2009).
- (2009) Nature Rev. Drug Discov. , vol.8 , pp. 447-448
- Storey, S.¹

7
- 59749092456
- Limits on Medicare's ability to control rising spending on cancer drugs
- Bach, P. B. Limits on Medicare's ability to control rising spending on cancer drugs. N. Engl. J. Med. 360, 626-633 (2009).
- (2009) N. Engl. J. Med. , vol.360 , pp. 626-633
- Bach, P.B.¹

8
- 84957940642
- WHO WHO website [online]
- WHO. Cancer. WHO website [online], http://www.who.int/cancer/en (2010).
- (2010) Cancer

9
- 54949085398
- K-ras mutations and benefit from cetuximab in advanced colorectal cancer
- Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757-1765 (2008).
- (2008) N. Engl. J. Med. , vol.359 , pp. 1757-1765
- Karapetis, C.S.¹

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.